Applied Biosystems has been put at a big disadvantage in an important sequencing patent issue after a key licensing partner was recently named the junior party in a patent interference review triggered by the allowance of an Enzo Biochem patent on DNA sequencing technology.
 
According to a patent attorney with experience in the interference review process, statistics show that companies named a junior party have little chance of winning the US patent office’s designation as original inventor.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.